Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

BRAFnon-V600E more frequently co-occurs with IDH1/2 mutations in adult patients with gliomas than in patients harboring BRAFV600E but without a survival advantage.

BMC neurology - 12 May 2021

Wang Wei, Wang Maode, Jiang Haitao, Wang Tuo, Da Rong

Abstract excerpt

BACKGROUND: The effects of BRAFnon-V600E and BRAFV600E on the outcomes and the molecular characteristics of adult glioma patients are unknown and need to be explored, although BRAFV600E has been extensively studied in pediatric glioma. METHODS: Co-occurring mutations and copy number alterations of associated genes in the MAPK and p53 pathways were investigated using data from The Cancer Genome Atlas (TCGA) public...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Brain Neoplasms
Share to Glioblastoma

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Glioma

Share to Homozygote

Share to Isocitrate Dehydrogenase

Share to Prognosis

Share to Proto-Oncogene Proteins B-raf

Share to Survival Analysis

Source

Open in PubMed Open full text

Identifiers

PMID: 33980169
DOI: 10.1186/s12883-021-02224-6
PMCID: PMC8114535

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

BRAFnon-V600E more frequently co-occurs with IDH1/2 mutations in adult patients with gliomas than in patients harboring BRAFV600E but without a survival advantage.PMID 33980169Read ↗

BRAFnon-V600E more frequently co-occurs with IDH1/2 mutation in adult patients with gliomas than patients harboring BRAFV600E, but without survival advantageSemantic proximity Read ↗

BRAFAMP Frequently Co-occurs With IDH1/2, TP53, and ATRX Mutations in Adult Patients With Gliomas and Is Associated With Poorer Survival Than That of Patients Harboring BRAFV600ESemantic proximity Read ↗

Integrated molecular and clinical analysis of BRAF-mutant glioma in adultsSemantic proximity Read ↗

IDH-mutant gliomas with additional class-defining molecular events.Semantic proximity Read ↗

Additional genetic alterations in BRAF-mutant gliomas correlate with histologic diagnoses.Semantic proximity Read ↗

A Genome-Wide Profiling of Glioma Patients with an IDH1 Mutation Using the Catalogue of Somatic Mutations in Cancer DatabaseSemantic proximity Read ↗

Structural variants shape driver combinations and outcomes in pediatric high-grade gliomaSemantic proximity Read ↗

Integrated genomic characterization of cancer genes in gliomaSemantic proximity Read ↗

Non-canonical IDH1 and IDH2 mutations: a clonal and relevant event in an Italian cohort of gliomas classified according to the 2016 World Health Organization (WHO) criteria.Semantic proximity Read ↗

A review of recently described genetic alterations in central nervous system tumors.Semantic proximity Read ↗

BRAF-amplified glioblastoma patients have a worse prognosis than those with BRAF mutation and are associated with amplification of MET, RHEB and CUL1.Semantic proximity Read ↗

Age-dependent Non-silent Somatic Mutation with Transcriptomic Landscape and Prognosis of Lower Grade GliomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.